{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:15:55Z","timestamp":1781788555969,"version":"3.54.5"},"reference-count":177,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fondazione Regionale per la Ricerca Biomedica (FRRB, Regione Lombardia)","award":["CP2_10\/2018"],"award-info":[{"award-number":["CP2_10\/2018"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>MPM has a uniquely poor somatic mutational landscape, mainly driven by environmental selective pressure. This feature has dramatically limited the development of effective treatment. However, genomic events are known to be associated with MPM progression, and specific genetic signatures emerge from the exceptional crosstalk between neoplastic cells and matrix components, among which one main area of focus is hypoxia. Here we discuss the novel therapeutic strategies focused on the exploitation of MPM genetic asset and its interconnection with the surrounding hypoxic microenvironment as well as transcript products and microvesicles representing both an insight into the pathogenesis and promising actionable targets.<\/jats:p>","DOI":"10.3390\/ijms24043496","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T02:56:13Z","timestamp":1675997773000},"page":"3496","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Genes\u2013Stemness\u2013Secretome Interplay in Malignant Pleural Mesothelioma: Molecular Dynamics and Clinical Hints"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0929-4394","authenticated-orcid":false,"given":"Giulia M.","family":"Stella","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Medical Therapeutics, University of Pavia Medical School, 27100 Pavia, Italy"},{"name":"Unit of Respiratory Diseases, Cardiothoracic and Vascular Department, IRCCS Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2024-6131","authenticated-orcid":false,"given":"Caterina","family":"Marchi\u00f2","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Turin, 10124 Turin, Italy"},{"name":"Pathology Unit, FPO-IRCCS Candiolo Cancer Institute, Strada Provinciale 142, 10060 Candiolo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0241-0620","authenticated-orcid":false,"given":"Elia","family":"Bari","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Piemonte Orientale, Largo Donegani 2\/3, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4892-4192","authenticated-orcid":false,"given":"Ilaria","family":"Ferrarotti","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Therapeutics, University of Pavia Medical School, 27100 Pavia, Italy"},{"name":"Unit of Respiratory Diseases, Cardiothoracic and Vascular Department, IRCCS Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco R.","family":"Bertuccio","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Therapeutics, University of Pavia Medical School, 27100 Pavia, Italy"},{"name":"Unit of Respiratory Diseases, Cardiothoracic and Vascular Department, IRCCS Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Di Gennaro","sequence":"additional","affiliation":[{"name":"Unit of Respiratory Diseases, Cardiothoracic and Vascular Department, IRCCS Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Michael","family":"Abbott","sequence":"additional","affiliation":[{"name":"Department of Surgical, Pediatric and Diagnostic Sciences, University of Pavia, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Putignano","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Therapeutics, University of Pavia Medical School, 27100 Pavia, Italy"},{"name":"Unit of Respiratory Diseases, Cardiothoracic and Vascular Department, IRCCS Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4423-2482","authenticated-orcid":false,"given":"Ilaria","family":"Campo","sequence":"additional","affiliation":[{"name":"Unit of Respiratory Diseases, Cardiothoracic and Vascular Department, IRCCS Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8062-6836","authenticated-orcid":false,"given":"Maria Luisa","family":"Torre","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Piemonte Orientale, Largo Donegani 2\/3, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo G.","family":"Corsico","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Therapeutics, University of Pavia Medical School, 27100 Pavia, Italy"},{"name":"Unit of Respiratory Diseases, Cardiothoracic and Vascular Department, IRCCS Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1183\/09059180.00007014","article-title":"Malignant pleural mesothelioma: History, controversy and future of a manmade epidemic","volume":"24","author":"Stella","year":"2015","journal-title":"Eur. Respir. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.21037\/dmr-22-19","article-title":"Malignant peritoneal mesothelioma literature review: Past, present, and future","volume":"5","author":"Gregory","year":"2022","journal-title":"Dig. Med. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1136\/thoraxjnl-2021-217709","article-title":"Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: A population-based study","volume":"77","author":"Belderbos","year":"2022","journal-title":"Thorax"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/thoraxjnl-2013-204161","article-title":"Mesothelioma risk after 40 years since first exposure to asbestos: A pooled analysis","volume":"69","author":"Reid","year":"2014","journal-title":"Thorax"},{"key":"ref_5","first-page":"e2100422","article-title":"Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape","volume":"6","author":"Madison","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41379-021-00895-7","article-title":"Pleural mesothelioma classification-update and challenges","volume":"35","author":"Dacic","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.21037\/jtd.2017.10.09","article-title":"Clinical diagnosis of malignant pleural mesothelioma","volume":"10","author":"Bianco","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1479-5876-10-12","article-title":"Cancers of unknown primary origin: Current perspectives and future therapeutic strategies","volume":"10","author":"Stella","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","article-title":"The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification","volume":"17","author":"Sauter","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Lettieri, S., Bortolotto, C., Agustoni, F., Lococo, F., Lancia, A., Comoli, P., Corsico, A.G., and Stella, G.M. (2021). The Evolving Landscape of the Molecular Epidemiology of Malignant Pleural Mesothelioma. J. Clin. Med., 10.","DOI":"10.3390\/jcm10051034"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.cell.2007.08.006","article-title":"Modeling Tissue Morphogenesis and Cancer in 3D","volume":"130","author":"Yamada","year":"2007","journal-title":"Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The Hallmarks of Cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"ref_13","first-page":"16","article-title":"Multiple distant metastases in a case of malignant pleural mesothelioma","volume":"13","author":"Tertemiz","year":"2014","journal-title":"Respir. Med. Case Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jons.2017.11.003","article-title":"Malignant pleural mesothelioma with rarely seen metastases","volume":"3","year":"2017","journal-title":"J. Oncol. Sci."},{"key":"ref_15","first-page":"100077","article-title":"Pancreatic metastasis from malignant pleural mesothelioma. An extremely rare site of metastasis in a patient with a very prolonged survival of seven years","volume":"4","author":"Mitsimponas","year":"2021","journal-title":"Curr. Probl. Cancer Case Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mrrev.2019.03.001","article-title":"Genetic predisposition for malignant mesothelioma: A concise review","volume":"781","author":"Betti","year":"2019","journal-title":"Mutat. Res. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2478\/raon-2019-0016","article-title":"The influence of genetic variability of DNA repair mechanisms on the risk of malignant mesothelioma","volume":"53","author":"Levpuscek","year":"2019","journal-title":"Radiol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2478\/raon-2019-0009","article-title":"Genetic polymorphisms in aquaporin 1 as risk factors for malignant mesothelioma and biomarkers of response to cisplatin treatment","volume":"53","author":"Senk","year":"2019","journal-title":"Radiol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.mrfmmm.2011.01.001","article-title":"XRCC1 and ERCC1 variants modify malignant mesothelioma risk: A case\u2013control study","volume":"708","author":"Betti","year":"2011","journal-title":"Mutat. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2478\/raon-2018-0004","article-title":"The influence of genetic variability on the risk of developing malignant mesothelioma","volume":"52","author":"Franko","year":"2018","journal-title":"Radiol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12935-022-02597-9","article-title":"DNA repair and damage pathways in mesothelioma development and therapy","volume":"22","author":"Malakoti","year":"2022","journal-title":"Cancer Cell Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc3459","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.jtho.2016.06.020","article-title":"BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study","volume":"11","author":"Righi","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Crovella, S., Moura, R.R., Brand\u00e3o, L., Vita, F., Schneider, M., Zanconati, F., Finotto, L., Zacchi, P., Zabucchi, G., and Borelli, V. (2022). Variant Enrichment Analysis to Explore Pathways Disruption in a Necropsy Series of Asbestos-Exposed Shipyard Workers. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232113628"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/15287394.2015.1123452","article-title":"Iron signature in asbestos-induced malignant pleural mesothelioma: A population-based autopsy study","volume":"79","author":"Crovella","year":"2016","journal-title":"J. Toxicol. Environ. Health A"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1080\/15287394.2019.1694612","article-title":"Pleural mesothelioma and lung cancer: The role of asbestos exposure and genetic variants in selected iron metabolism and inflammation genes","volume":"82","author":"Celsi","year":"2019","journal-title":"J. Toxicol. Environ. Health A"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"784081","DOI":"10.3389\/fonc.2021.784081","article-title":"Biological Pathways Associated with the Development of Pulmonary Toxicities in Mesothelioma Patients Treated with Radical Hemithoracic Radiation Therapy: A Preliminary Study","volume":"11","author":"Crovella","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1750-9378-7-25","article-title":"NLRP1 polymorphisms in patients with asbestos-associated mesothelioma","volume":"7","author":"Girardelli","year":"2012","journal-title":"Infect. Agent Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13027-015-0022-0","article-title":"NLRP1 and NLRP3 polymorphisms in mesothelioma patients and asbestos exposed individuals a population-based autopsy study from North East Italy","volume":"10","author":"Borelli","year":"2015","journal-title":"Infect. Agent Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.21037\/atm.2017.06.26","article-title":"Malignant pleural mesothelioma: Predictors and staging","volume":"5","author":"Richards","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.12688\/f1000research.15796.1","article-title":"Multimodality treatment of malignant pleural mesothelioma","volume":"7","author":"Berzenji","year":"2018","journal-title":"F1000Research"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2017.06.028","article-title":"Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma","volume":"405","author":"Betti","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Trassl, L., and Stathopoulos, G.T. (2022). KRAS Pathway Alterations in Malignant Pleural Mesothelioma: An Underestimated Player. Cancers, 14.","DOI":"10.3390\/cancers14174303"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/ijc.25763","article-title":"ERK2 is essential for the growth of human epithelioid malignant mesotheliomas","volume":"129","author":"Shukla","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/ijc.23949","article-title":"Genoic events associated with progression of pleural malignant mesothelioma","volume":"124","author":"Ivanov","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1517\/13543784.2010.522988","article-title":"Targeting the MET oncogene in cancer and metastases","volume":"19","author":"Stella","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/0008-5472.CAN-04-4567","article-title":"Functional analysis of c-Met\/hepatocyte growth factor pathway in malignant pleural mesothelioma","volume":"66","author":"Jagadeeswaran","year":"2006","journal-title":"Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Santoni-Rugiu, E., L\u00fc, M.J.S., Jakobsen, J.N., Melchior, L.C., Ravn, J., and S\u00f8rensen, J.B. (2021). Correlation of MET-Receptor Overexpression with MET Gene Amplification and Patient Outcome in Malignant Mesothelioma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222312868"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.anndiagpath.2016.04.007","article-title":"c-Met expression and MET amplification in malignant pleural mesothelioma","volume":"23","author":"Bois","year":"2016","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jtho.2015.10.019","article-title":"MET Gene Status in Malignant Mesothelioma Using Fluorescent In Situ Hybridization","volume":"11","author":"Varesano","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Ramundo, V., Zanirato, G., and Aldieri, E. (2021). The Epithelial-to-Mesenchymal Transition (EMT) in the Development and Metastasis of Malignant Pleural Mesothelioma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222212216"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e31756","DOI":"10.7554\/eLife.31756","article-title":"TGF-\u03b2 uses a novel mode of receptor activation to phosphorylate SMAD1\/5 and induce epithelial-to-mesenchymal transition","volume":"7","author":"Ramachandran","year":"2018","journal-title":"eLife"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/cr.2009.5","article-title":"TGF-\u03b2-induced epithelial to mesenchymal transition","volume":"19","author":"Xu","year":"2009","journal-title":"Cell Res."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kanteti, R., Dhanasingh, I., Kawada, I., Lennon, F.E., Arif, Q., Bueno, R., Hasina, R., Husain, A.N., Vigneswaran, W., and Seiwert, T. (2014). MET and PI3K\/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0105919"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1038\/bjc.2014.220","article-title":"Multipoint targeting of the PI3K\/mTOR pathway in mesothelioma","volume":"110","author":"Zhou","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2147\/IJN.S186344","article-title":"Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: An in vitro study","volume":"14","author":"Cova","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e1757","DOI":"10.1038\/cddis.2015.124","article-title":"Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K\/mTOR inhibitors","volume":"6","author":"Echeverry","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3892\/ijo.2012.1462","article-title":"Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo","volume":"41","author":"Miyoshi","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/embor.2008.74","article-title":"A reciplocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells","volume":"9","author":"Burk","year":"2008","journal-title":"EMBO Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.trecan.2020.09.003","article-title":"Extracellular Vesicles in Cancer Detection: Hopes and Hypes","volume":"7","author":"Hu","year":"2021","journal-title":"Trends Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nrg.2016.49","article-title":"Coming of age: Ten years of next-generation sequencing technologies","volume":"7","author":"Goodwin","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"a036269","DOI":"10.1101\/cshperspect.a036269","article-title":"The Impact of Next-Generation Sequencing on Cancer Genomics: From Discovery to Clinic","volume":"9","author":"Mardis","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_54","first-page":"2331","article-title":"Genome-based Mutational Analysis by Next Generation Sequencing in Patients with Malignant Pleural and Peritoneal Mesothelioma","volume":"36","author":"Ugurluer","year":"2016","journal-title":"Anticancer. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","article-title":"Molecular classification of malignant pleural mesothelioma: Identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition","volume":"20","author":"Jaurand","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","article-title":"Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: A retrospective study","volume":"10","author":"Monica","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejca.2021.12.023","article-title":"Malignant pleural mesothelioma: Germline variants in DNA repair genes may steer tailored treatment","volume":"163","author":"Sculco","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic landscape of pleural and peritoneal mesothelioma tumours","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3389\/fgene.2020.00899","article-title":"Identification of a Five-Gene Signature for Predicting Survival in Malignant Pleural Mesothelioma Patients","volume":"11","author":"Bai","year":"2020","journal-title":"Front. Genet."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13073-022-01060-8","article-title":"Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma","volume":"14","author":"Creaney","year":"2022","journal-title":"Genome Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-021-21798-w","article-title":"Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrc1367","article-title":"Exploiting tumour hypoxia in cancer treatment","volume":"4","author":"Brown","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrc3064","article-title":"Targeting hypoxia in cancer therapy","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41571-021-00539-4","article-title":"Therapeutic targeting of the hypoxic tumour microenvironment","volume":"18","author":"Singleton","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41389-017-0011-9","article-title":"The hypoxic tumour microenvironment","volume":"7","author":"Petrova","year":"2018","journal-title":"Oncogenesis"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fonc.2020.00126","article-title":"Antiangiogeneic Strategies in Mesothelioma","volume":"10","author":"Nowak","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"340","DOI":"10.18632\/genesandcancer.124","article-title":"Switching off malignant mesothelioma: Exploiting the hypoxic microenvironment","volume":"7","author":"Nabavi","year":"2016","journal-title":"Genes Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Kim, M.C., Hwang, S.H., Kim, N.Y., Lee, H.-S., Ji, S., Yang, Y., and Kim, Y. (2018). Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4720-z"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cmet.2006.02.002","article-title":"HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia","volume":"3","author":"Kim","year":"2006","journal-title":"Cell Metab."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.ejca.2012.01.016","article-title":"Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma","volume":"48","author":"Kaira","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Taralli, S., Giancipoli, R.G., Caldarella, C., Scolozzi, V., Ricciardi, S., Cardillo, G., and Calcagni, M.L. (2021). The Prognostic Value of 18F-FDG PET Imaging at Staging in Patients with Malignant Pleural Mesothelioma: A Literature Review. J. Clin. Med., 11.","DOI":"10.3390\/jcm11010033"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00259-013-2561-1","article-title":"The association of 18F-FDG PET\/CT parameters with survival in malignant pleural mesothelioma","volume":"41","author":"Klabatsa","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1535-6108(03)00085-0","article-title":"Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene","volume":"3","author":"Pennacchietti","year":"2003","journal-title":"Cancer Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.21873\/anticanres.14140","article-title":"Hypoxia Inducible Factor-1\u03b1 Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells","volume":"40","author":"Shukuya","year":"2020","journal-title":"Anticancer. Res."},{"key":"ref_76","first-page":"9","article-title":"Mesothelioma and Hypoxia: Modulation of the Inflammation-Related Phenotype and Identification of Prognostic Markers","volume":"6","author":"Ravenna","year":"2014","journal-title":"J. Cancer Sci. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1159\/000485821","article-title":"Hypoxia Accelerates Aggressiveness of Hepatocellular Carcinoma Cells Involving Oxidative Stress, Epithelial-Mesenchymal Transition and Non-Canonical Hedgehog Signaling","volume":"44","author":"Liu","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1038\/s41598-017-02694-0","article-title":"Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism","volume":"7","author":"Melaiu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41416-020-0912-9","article-title":"Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds","volume":"123","author":"Sciarrillo","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"121","DOI":"10.32471\/exp-oncology.2312-8852.vol-44-no-2.18045","article-title":"Chemoresistance related to hypoxia Adaptation in mesothelioma cells from tumor spheroids","volume":"44","author":"Endoh","year":"2022","journal-title":"Exp. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2005.07.010","article-title":"Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM)","volume":"51","author":"Klabatsa","year":"2006","journal-title":"Lung Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0092-8674(01)00409-3","article-title":"The evolving concept of a stem cell: Entity or function?","volume":"105","author":"Blau","year":"2001","journal-title":"Cell"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nm.2304","article-title":"The cancer stem cell: Premises, promises and challenges","volume":"17","author":"Clevers","year":"2011","journal-title":"Nat. Med."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Tu, S.M., Zhang, M., Wood, C.G., and Pisters, L.L. (2021). Stem Cell Theory of Cancer: Origin of Tumor Heterogeneity and Plasticity. Cancers, 13.","DOI":"10.3390\/cancers13164006"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41568-018-0056-x","article-title":"Stem cell fate in cancer growth, progression and therapy resistance","volume":"18","author":"Lytle","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrg1475","article-title":"The nature of stem cells: State rather than entity","volume":"5","author":"Zipori","year":"2004","journal-title":"Nat. Rev. Genet."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/nm.4409","article-title":"Cancer stem cells revisited","volume":"23","author":"Batlle","year":"2017","journal-title":"Nat. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/nature04957","article-title":"The stem-cell niche as an entity of action","volume":"441","author":"Scadden","year":"2006","journal-title":"Nature"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nri.2017.53","article-title":"Adult haematopoietic stem cell niches","volume":"17","author":"Crane","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1158\/0008-5472.CAN-05-3986","article-title":"Normal stem cells and cancer stem cells: The niche matters","volume":"66","author":"Li","year":"2006","journal-title":"Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrm2319","article-title":"No place like home: Anatomy and function of the stem cell niche","volume":"9","author":"Jones","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood-2015-07-533588","article-title":"The hematopoietic stem cell niche in homeostasis and disease","volume":"126","author":"Calvi","year":"2015","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/stem.2487","article-title":"Concise Review: The Malignant Hematopoietic Stem Cell Niche","volume":"35","author":"Yao","year":"2017","journal-title":"Stem Cells"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00018-016-2306-y","article-title":"The hematopoietic stem-cell niche in health and leukemia","volume":"74","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.stem.2015.02.015","article-title":"The cancer stem cell niche: How essential is the niche in regulating stemness of tumor cells?","volume":"16","author":"Plaks","year":"2015","journal-title":"Cell Stem Cell"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nrc2344","article-title":"Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability","volume":"8","author":"Bristow","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Abbott, D.M., Bortolotto, C., Benvenuti, S., Lancia, A., Filippi, A.R., and Stella, G.M. (2020). Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge. Cancers, 12.","DOI":"10.3390\/cancers12051186"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Wu, L., Blum, W., Zhu, C.Q., Yun, Z., Pecze, L., Kohno, M., Chan, M.L., Zhao, Y., Felley-Bosco, E., and Schwaller, B. (2018). Putative cancer stem cells may be the key target to inhibit cancer cell repopulation between the intervals of chemoradiation in murine mesothelioma. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4354-1"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ccr.2009.03.018","article-title":"Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells","volume":"15","author":"Li","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"6816","DOI":"10.1158\/0008-5472.CAN-13-0615","article-title":"RNAi-mediated silencing of Myc transcription inhibits stem-like cell maintenance and tumorigenicity in prostate cancer","volume":"73","author":"Civenni","year":"2013","journal-title":"Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","article-title":"Targeting cancer stem cell pathways for cancer therapy","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3389\/fonc.2019.01366","article-title":"The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy","volume":"9","author":"Chu","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1080\/21645515.2021.1917933","article-title":"Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma","volume":"17","author":"Metro","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Assi\u00e9, J.B., Cr\u00e9pin, F., Grolleau, E., Canellas, A., Geier, M., Gr\u00e9bert-Manuardi, A., Akkache, N., Renault, A., Hauss, P.A., and Sabatini, M. (2022). Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study. Cancers, 14.","DOI":"10.3390\/cancers14061498"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"89722","DOI":"10.18632\/oncotarget.21113","article-title":"Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients","volume":"8","author":"Marcq","year":"2017","journal-title":"Oncotarget"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Cedr\u00e9s, S., Ponce-Aix, S., Zugazagoitia, J., Sansano, I., Enguita, A., Navarro-Mendivil, A., Martinez-Marti, A., Martinez, P., and Felip, E. (2015). Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0121071"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1758835920962362","DOI":"10.1177\/1758835920962362","article-title":"PD-L1 and prognosis in patients with malignant pleural mesothelioma: A meta-analysis and bioinformatics study","volume":"12","author":"Jin","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1601482","DOI":"10.1080\/2162402X.2019.1601482","article-title":"Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion","volume":"8","author":"Bertino","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: Recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"111ra120","DOI":"10.1126\/scitranslmed.3003130","article-title":"The PDL1-PD1 axis converts human TH1 cells into regulatory T cells","volume":"3","author":"Amarnath","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/s41467-018-04313-6","article-title":"STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion","volume":"9","author":"Hsu","year":"2018","journal-title":"Nat. Comm."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3958908","DOI":"10.1155\/2019\/3958908","article-title":"PD-L1 Expression in Human Breast Cancer Stem Cells Is Epigenetically Regulated through Posttranslational Histone Modifications","volume":"2019","author":"Darvin","year":"2019","journal-title":"J. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"103698","DOI":"10.1016\/j.critrevonc.2022.103698","article-title":"The application of cancer stem cell model in malignant mesothelioma","volume":"174","author":"Bronte","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.bbrc.2010.12.054","article-title":"Identification of cancer stem cell markers in human malignant mesothelioma cells","volume":"404","author":"Ghani","year":"2011","journal-title":"Biochem. Biophys. Res. Comm."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bbrc.2012.02.054","article-title":"Characterization of cancer stem cell properties of CD24 and CD26-positive human malignant mesothelioma cells","volume":"419","author":"Yamazaki","year":"2012","journal-title":"Biochem. Biophys. Res. Comm."},{"key":"ref_118","first-page":"437","article-title":"Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed","volume":"37","author":"Carboni","year":"2010","journal-title":"Int. J. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Pasdar, E.A., Smits, M., Stapelberg, M., Bajzikova, M., Stantic, M., Goodwin, J., Yan, B., Stursa, J., Kovarova, J., and Sachaphibulkij, K. (2015). Characterisation of mesothelioma-initiating cells and their susceptibility to anti-cancer agents. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0119549"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd.2018.157","article-title":"Cancer stem cell pipeline flounders","volume":"17","author":"Garber","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"18573","DOI":"10.1074\/jbc.M110.200717","article-title":"Compensatory function of Pyk2 protein in the promotion of focal adhesion kinase (FAK)-null mammary cancer stem cell tumorigenicity and metastatic activity","volume":"286","author":"Fan","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1038\/s41598-019-41116-1","article-title":"Non-redundant functions of FAK and Pyk2 in intestinal epithelial repair","volume":"9","author":"Thomas","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/iub.303","article-title":"Integrin signaling through FAK in the regulation of mammary stem cells and breast cancer","volume":"2","author":"Guan","year":"2010","journal-title":"IUBMB Life"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","article-title":"Maintenance Defactinib Versus Placebo after First-Line Chemotherapy in Patients with Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study","volume":"37","author":"Fennell","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1021\/acs.biochem.9b00541","article-title":"Conformational Dynamics of FERM-Mediated Autoinhibition in Pyk2 Tyrosine Kinase","volume":"58","author":"Loving","year":"2019","journal-title":"Biochemistry"},{"key":"ref_126","first-page":"1227","article-title":"Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer","volume":"55","author":"Sekido","year":"1995","journal-title":"Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Sato, T., and Sekido, Y. (2018). NF2\/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19040988"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0092-8674(93)90406-G","article-title":"A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor","volume":"72","author":"Trofatter","year":"1993","journal-title":"Cell"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Pignochino, Y., Dell\u2019Aglio, C., Inghilleri, S., Zorzetto, M., Basiric\u00f2, M., Capozzi, F., Canta, M., Piloni, D., Cemmi, F., and Sangiolo, D. (2015). The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1363-1"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1440-1827.2011.02666.x","article-title":"Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation","volume":"61","author":"Sekido","year":"2011","journal-title":"Pathol. Int."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.21037\/jtd.2017.09.34","article-title":"Essential signalling in NF2 loss-related tumours: The therapeutic potential of CRL4DCAF1 and mTOR combined inhibition","volume":"9","author":"Yang","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.stem.2008.06.005","article-title":"Nf2\/merlin regulates hematopoietic stem cell behavior by altering microenvironmental architecture","volume":"3","author":"Larsson","year":"2008","journal-title":"Cell Stem Cell"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.stemcr.2017.02.005","article-title":"(Stem Cell Factor-Based Identification and Functional Properties of In Vitro-Selected Subpopulations of Malignant Mesothelioma Cells","volume":"8","author":"Blum","year":"2017","journal-title":"Stem Cell Rep."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e12640","DOI":"10.15252\/emmm.202012640","article-title":"Mithramycin induces promoter reprogramming and differentiation of rhabdoid tumor","volume":"13","author":"Chasse","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1158\/1078-0432.CCR-14-3379","article-title":"Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells","volume":"22","author":"Rao","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fgene.2019.00125","article-title":"MicroRNAs, Hypoxia and the Stem-Like State as Contributors to Cancer Aggressiveness","volume":"10","author":"Macharia","year":"2019","journal-title":"Front. Genet."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3389\/fgene.2014.00008","article-title":"Competing endogenous RNAs (ceRNAs): New entrants to the intricacies of gene regulation","volume":"5","author":"Kartha","year":"2014","journal-title":"Front. Genet."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrg2814","article-title":"Annotating non-coding regions of the genome","volume":"11","author":"Alexander","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Moriondo, G., Scioscia, G., Soccio, P., Tondo, P., De Pace, C.C., Sabato, R., Foschino Barbaro, M.P., and Lacedonia, D. (2022). Effect of Hypoxia-Induced Micro-RNAs Expression on Oncogenesis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23116294"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/10409238.2022.2088684","article-title":"Hypoxia-regulated microRNAs: The molecular drivers of tumor progression","volume":"57","author":"Sawai","year":"2022","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/aps.2012.195","article-title":"Hypoxia-regulated microRNAs in human cancer","volume":"34","author":"Shen","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1089\/ars.2013.5639","article-title":"HypoxamiRs and cancer: From biology to targeted therapy","volume":"21","author":"Gee","year":"2014","journal-title":"Antioxidants Redox Signal."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Hua, Z., Lv, Q., Ye, W., Wong, C.K., Cai, G., Gu, D., Ji, Y., Zhao, C., Wang, J., and Yang, B.B. (2006). MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS ONE, 1.","DOI":"10.1371\/journal.pone.0000116"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3389\/fonc.2020.00105","article-title":"Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future","volume":"10","author":"Reid","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S1470-2045(17)30596-X","article-title":"miR-16: Expanding the range of molecular targets in mesothelioma","volume":"18","author":"Fennell","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.21037\/tlcr.2017.12.01","article-title":"An innovative mesothelioma treatment based on miR-16 mimic loaded EGFR targeted minicells (TargomiRs)","volume":"7","author":"Viteri","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1038\/oncsis.2012.33","article-title":"MicroRNAs in colorectal cancer stem cells: New regulators of cancer stemness?","volume":"1","author":"Caruso","year":"2012","journal-title":"Oncogenesis"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.4081\/oncol.2013.e8","article-title":"The Role of microRNAs in Stemness of Cancer Stem Cells","volume":"7","author":"Bavarsad","year":"2013","journal-title":"Oncol. Rev."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Ma, Y., Shen, N., Wicha, M.S., and Luo, M. (2021). The Roles of the Let-7 Family of MicroRNAs in the Regulation of Cancer Stemness. Cells, 10.","DOI":"10.3390\/cells10092415"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Flores-Huerta, N., Silva-C\u00e1zares, M.B., Arriaga-Pizano, L.A., Prieto-Ch\u00e1vez, J.L., and L\u00f3pez-Camarillo, C. (2021). LncRNAs and microRNAs as Essential Regulators of Stemness in Breast Cancer Stem Cells. Biomolecules, 11.","DOI":"10.3390\/biom11030380"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jconrel.2019.07.022","article-title":"Mesenchymal stem\/stromal cell secretome for lung regeneration: The long way through \u201cpharmaceuticalization\u201d for the best formulation","volume":"309","author":"Bari","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jconrel.2017.07.023","article-title":"Mesenchymal stem\/stromal cell extracellular vesicles: From active principle to next generation drug delivery system","volume":"262","author":"Crivelli","year":"2017","journal-title":"J. Control Release"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"102174","DOI":"10.1016\/j.redox.2021.102174","article-title":"Ferroptosis-dependent extracellular vesicles from macrophage contribute to asbestos-induced mesothelial carcinogenesis through loading ferritin","volume":"47","author":"Ito","year":"2021","journal-title":"Redox Biol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41580-019-0158-7","article-title":"Extracellular vesicles: A new communication paradigm?","volume":"20","author":"Raposo","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41590-021-00899-0","article-title":"Extracellular vesicles in immunomodulation and tumor progression","volume":"22","author":"Marar","year":"2021","journal-title":"Nat. Immunol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/pmic.201300389","article-title":"The roles of extracellular vesicles in cancer biology: Toward the development of novel cancer biomarkers","volume":"14","author":"Katsuda","year":"2014","journal-title":"Proteomics"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mam.2017.11.012","article-title":"The influence of tumour-derived extracellular vesicles on local and distal metastatic dissemination","volume":"60","author":"Nogues","year":"2018","journal-title":"Mol. Asp. Med."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"102949","DOI":"10.1016\/j.critrevonc.2020.102949","article-title":"Extracellular vesicles as biomarkers in malignant pleural mesothelioma: A review","volume":"150","author":"Ahmadzada","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1096\/fj.201701291RR","article-title":"Exosomes from asbestos-exposed cells modulate gene expression in mesothelial cells","volume":"32","author":"Munson","year":"2018","journal-title":"FASEB J."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1002\/jcb.26863","article-title":"Mouse serum exosomal proteomic signature in response to asbestos exposure","volume":"119","author":"Munson","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1089\/ars.2007.1909","article-title":"Iron Homeostasis in the lung following asbestos exposure","volume":"10","author":"Ghio","year":"2008","journal-title":"Antioxidants Redox Signal."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma","volume":"367","author":"Pass","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/978-1-0716-0759-6_10","article-title":"Extracellular Vesicles and Their Roles in Cancer Progression","volume":"2174","author":"Chang","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.yexcr.2014.01.014","article-title":"Tumor exosomes induce tunneling nanotubes in lipid raft-enriched regions of human mesothelioma cells","volume":"323","author":"Thayanithy","year":"2014","journal-title":"Exp. Cell Res."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"32643","DOI":"10.1038\/srep32643","article-title":"Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo","volume":"6","author":"Greening","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"103","DOI":"10.21873\/cgp.20023","article-title":"A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ","volume":"14","author":"Creaney","year":"2017","journal-title":"Cancer Genom. Proteom."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/S0002-9440(10)63739-X","article-title":"Proteomic analysis of exosomes secreted by human mesothelioma cells","volume":"164","author":"Hegmans","year":"2004","journal-title":"Am. J. Pathol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1165\/rcmb.2003-0238OC","article-title":"Proteomic analysis of exosomes isolated from human malignant pleural effusions","volume":"31","author":"Bard","year":"2004","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.canlet.2019.08.001","article-title":"Exosomal transfer of miR-126 promotes the anti-tumour response in malignant mesothelioma: Role of miR-126 in cancer-stroma communication","volume":"463","author":"Monaco","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"11688","DOI":"10.1038\/s41598-019-48133-0","article-title":"Exosomal miR-16-5p as a target for malignant mesothelioma","volume":"9","author":"Munson","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.bcmd.2005.03.003","article-title":"Exosomes and the MICA-NKG2D system in cancer","volume":"34","author":"Clayton","year":"2005","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"22492","DOI":"10.3402\/jev.v2i0.22492","article-title":"Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma","volume":"2","author":"Mahaweni","year":"2013","journal-title":"J. Extracell. Vesicles"},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Javadi, J., Goergens, A., Vanky, H., Gupta, D., Hjerpe, A., El-Andaloussi, S., Hagey, D., and Dobra, K. (2021). Diagnostic and Prognostic Utility of the Extracellular Vesicles Subpopulations Present in Pleural Effusion. Biomolecules, 11.","DOI":"10.3390\/biom11111606"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Cavalleri, T., Angelici, L., Favero, C., Dioni, L., Mensi, C., Bareggi, C., Palleschi, A., Rimessi, A., Consonni, D., and Bordini, L. (2017). Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0176680"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"e2100639","DOI":"10.1002\/adhm.202100639","article-title":"Liposomes and Extracellular Vesicles as Drug Delivery Systems: A Comparison of Composition, Pharmacokinetics, and Functionalization","volume":"11","author":"Gandek","year":"2022","journal-title":"Adv. Heal. Mater."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e12198","DOI":"10.1002\/jev2.12198","article-title":"Tumour-derived extracellular vesicle membrane hybrid lipid nanovesicles enhance siRNA delivery by tumour-homing and intracellular freeway transportation","volume":"11","author":"Zhou","year":"2022","journal-title":"J. Extracell. Vesicles"},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Chernova, T., Grosso, S., Sun, X.M., Tenor, A.R., Cabeza, J.Z., Craxton, A., Self, E.L., Nakas, A., Cain, K., and MacFarlane, M. (2022). Extracellular Vesicles Isolated from Malignant Mesothelioma Cancer-Associated Fibroblasts Induce Pro-Oncogenic Changes in Healthy Mesothelial Cells. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012469"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/3496\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:28:50Z","timestamp":1760120930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/3496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":177,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24043496"],"URL":"https:\/\/doi.org\/10.3390\/ijms24043496","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]}}}